© 1998


New Concepts and Targets for Therapy

  • Ian Rodger
  • Jack Botting
  • Sven-Erik Dahlén

Table of contents

  1. Front Matter
    Pages i-ix
  2. S.-E. Dahlén
    Pages 11-23
  3. A. W. Ford-Hutchinson, P.-J. Jakobsson
    Pages 25-34
  4. S. Nicosia, G. E. Rovati, V. Capra, S. Ravasi, M. Mezzetti, T. Viganò et al.
    Pages 35-42
  5. M. Kumlin
    Pages 43-54
  6. A. Szczeklik, M. Sanak
    Pages 79-88
  7. J. C. Kips, R. A. Pauwels
    Pages 89-94
  8. J.-P. Gascard, C. Brink
    Pages 103-110
  9. P. R. Devchand, W. Wahli
    Pages 119-124
  10. P. H. Howarth
    Pages 125-137
  11. Back Matter
    Pages 139-143

About this book


In the two decades since the elusive "slow reacting substance of anaphylaxis" (SRS-A) was identified as a product of the action of the 5-lipoxygenase enzyme on arachidonic acid, it has been well established that the leukotrienes are key mediators of both alIergy and inflammation. Their release by alIergen or other challenge has been demonstrated in the lungs of asthmatic subjects, and measurement of urinary leukotriene concentrations in such patients has been shown to be a valuable, non­ invasive indicator. Significant progress has been made towards the characterization of the leukotriene receptor subtypes, exemplified by the cloning of the LTB4 receptor earlier this year. Coupled with this there has been a continued elucidation of signal transduction mechanisms underlying receptor activation. Consequent upon these advances has been the development of potent antagonists of the CysLT receptor, J and both these and inhibitors of leukotriene biosynthesis have entered clinical practice in the therapy of asthma. In this clinical setting antagonists of the CysLTJ receptor have been shown to be an effective therapy in chronic asthmatics, against antigen- and exercise-induced bronchoconstriction, and in aspirin-intolerant asthmatics. The advent of this new class of agents promises to change the way in which asthmatic patients are currently treated.


asthma cardiovascular disease inflammation research

Editors and affiliations

  • Ian Rodger
    • 1
  • Jack Botting
    • 2
  • Sven-Erik Dahlén
    • 3
  1. 1.Merck Frosst Canada, Inc.Pointe-Claire-DorvalCanada
  2. 2.The William Harvey Research InstituteSaint Bartholomew’s Hospital Medical CollegeLondonUK
  3. 3.Asthma and Allergy Research, Institute of Environmental MedicineKarolinska InstitutetStockholmSweden

About the editors

Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK.

Bibliographic information

  • Book Title Leukotrienes
  • Book Subtitle New Concepts and Targets for Therapy
  • Editors Ian Rodger
    Jack H. Botting
    Sven-Erik Dahlén
  • DOI
  • Copyright Information Kluwer Academic Publishers and William Harvey Press 1998
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Hardcover ISBN 978-0-7923-8738-1
  • Softcover ISBN 978-94-010-6045-5
  • eBook ISBN 978-94-011-4880-1
  • Edition Number 1
  • Number of Pages IX, 143
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Pharmacology/Toxicology
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods